ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
Conjugate:
unconjugated
Clone:
85D4, monoclonal
Application:
DB, ELISA (i), WB
Citations:
12
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
85D4, monoclonal
contains
15 mM sodium azide
species reactivity
pig, sheep, rabbit, bovine, baboon, human, goat, canine
technique(s)
dot blot: suitable, indirect ELISA: 1:8,000, western blot: suitable
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
類似した製品をお探しですか? 訪問 製品比較ガイド
General description
Fibrinogen is a blood coagulation protein that consists of Aα, Bβ and γ polypeptide chains. Fibrinogen expression is induced by acute-inflammatory responses and has also been associated with the risk of cardiovascular disorders. Monoclonal Anti-Fibrinogen antibody recognizes a conformational epitope, which is destroyed by the cleavage of the γ (302-303) bond. This epitope is found in fibrinogen and in fibrin monomers (devoid of either fibrinopeptide A, or both A and B fibrinopeptides), when they are immobilized on ELISA plates. The antibody reacts with the D-dimer and D-fragment. It does not recognize individual fibrinogen/fibrin chains in denatured-reduced forms or their proteolytic fragments. The E fragment is not recognized by the antibody. The antibody reacts with greater avidity with protofibrils than with wider fibrin fibers in electron microscopic analysis. Monoclonal Anti-Fibrinogen is specific for fibrinogen and fibrin in humans, baboons, bovines, sheep, goats, pigs, rabbits and dogs.
Fibrinogen was the first blood coagulation factor to be identified, and it is a precursor of fibrin protein. The three polypeptide chains are coded by three genes located on human chromosome 4q23-q32, and spans 51kb.
Immunogen
human fibrin degradation products
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunofluorescence (1 paper)
Immunofluorescence (1 paper)
Monoclonal Anti-Fibrinogen antibody is suitable for use in indirect ELISA, dot blot (1:1000 using human fibrinogen), and western blot.
Monoclonal Anti-Fibrinogen antibody produced in mouse has been used in immunohistochemistry and confocal laser scanning microscopy.
Biochem/physiol Actions
Fibrinogen is an acute-phase inflammatory protein, which plays an essential role in blood clotting.
The product recognizes a conformational epitope, which is destroyed by the cleavage of the γ (302-303) bond. This epitope is found in both fibrinogen and in fibrin monomers, devoid of either fibrinopeptide A, or both A and B fibrinopeptides, when they are immobilized on ELISA plates. The antibody reacts with the D-dimer and D-fragment. It does not recognize individual fibrinogen/fibrin chains in the denatured-reduced form and their proteolytic fragments. The E fragment is not recognized by the antibody. Using electron microscopy, the antibody reacts with greater avidity with protofibrils than with wider fibrin fibers.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
F9902-.5ML: + F9902-.2ML: + F9902-VAR: + F9902-BULK:
jan
Katharina Gegenschatz-Schmid et al.
Acta biomaterialia, 137, 331-345 (2021-10-22)
Blood-contacting medical implants made of Nitinol and other titanium alloys, such as neurovascular flow diverters and peripheral stents, have the disadvantage of being highly thrombogenic. This makes the use of systemic (dual) anti-platelet/anticoagulant therapies inevitable with related risks of device
Martin T Matter et al.
ACS applied materials & interfaces, 13(28), 33300-33310 (2021-07-14)
Dental implant failure remains a prevalent problem around the globe. The integration of implants at the interface of soft and hard tissues is complex and susceptible to instability and infections. Modifications to the surface of titanium implants have been developed
Rodrigo Méndez Rojano et al.
PLoS computational biology, 18(10), e1010277-e1010277 (2022-10-04)
Over the past decade, much of the development of computational models of device-related thrombosis has focused on platelet activity. While those models have been successful in predicting thrombus formation in medical devices operating at high shear rates (> 5000 s-1)
Vincent Milleret et al.
Clinical implant dentistry and related research, 21 Suppl 1, 8-14 (2019-03-01)
Dental implants often have surface modifications that alter surface topography and chemistry to improve osseointegration and thereby increase treatment predictability. Surface contact-induced blood coagulation is associated with the onset of osseointegration. To quantitatively evaluate the thrombogenicity of two commercially available
Re-evaluation of sarcolemma injury and muscle swelling in human skeletal muscles after eccentric exercise
Yu Ji-Guo, et al
PLoS ONE, 8(4), e62056-e62056 (2013)
関連コンテンツ
Instructions
Datasheet
Datasheet
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)